StockData

Amprius Technologies vs Ultralife

AMPX and ULBI side by side, both in electronic and other electrical equipment and components, except computer equipment. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AMPX and ULBI compare

Amprius Technologies is the larger company, worth 4.4 times as much as Ultralife ($1.2B against $262M).

Amprius Technologies grew revenue faster over the last twelve months (117% versus 3.0% for Ultralife).

Ultralife keeps more of each dollar of sales as profit, with a net margin of −1.5% compared with −28.4% at Amprius Technologies.

Amprius Technologies scores higher on the StockData Score (12 against 7 for Ultralife), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAMPXULBI
Size and price
Market cap$1.2B$262M
Share price$7.93$15.73
Change, 1 year−35.9%173%
Change, 5 years–171%
Beta (5Y)1.950.85
Employees97678
StockData Score
Total score12 (better)7
Valuation score00
Growth score4 (better)3
Performance score22
Health score6 (better)2
Dividend score00
Valuation
P/S9.1×1.4× (better)
P/B9.3×1.9× (better)
FCF yield−5.3%−0.26% (better)
Fair value$6.48$7.69
Margin of safety−22.3% (better)−105%
Growth
Revenue growth (TTM)117% (better)3.0%
Revenue growth, 5Y average–12.2%
Net income growth (TTM)–−272%
Profitability
Gross margin24.8%25.7% (better)
Operating margin−32.4%−2.2% (better)
Net margin−28.4%−1.5% (better)
FCF margin−48.7%−0.36% (better)
Return on equity−31.7%−2.2% (better)
Return on invested capital−69.2%−1.9% (better)
Financial health
Debt / equity0.000.38 (better)
Current ratio4.21 (better)2.97
Altman Z-score16.39 (better)2.74
Piotroski F-score6 (better)4
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions66.7%32.1%
Held by insiders7.5%41.4%
Insider net buying, 12 months−$74.1M$2.2M (better)
Short interest, % of float16.1%0.66%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.